Table 1 Demographics for healthy volunteers (HVs) and individuals with treatment-resistant depression (TRD) showing mean values and standard error in brackets.

From: Hippocampal volume changes after (R,S)-ketamine administration in patients with major depressive disorder and healthy volunteers

 

3T

7T

HV (N = 18)

TRD (N = 26)

HV (N = 17)

TRD (N = 30)

Gender

 F

12 (66.7%)

16 (61.5%)

10 (58.8%)

17 (56.7%)

 M

6 (33.3%)

10 (38.5%)

7 (41.2%)

13 (43.3%)

Age

 Mean (SD)

33.7 (11.0)

34.0 (8.40)

34.0 (11.1)

33.9 (8.54)

 Median [Min, Max]

30.5 [20.0, 56.0]

32.0 [20.0, 55.0]

29.0 [20.0, 56.0]

32.0 [20.0, 55.0]

BMI

 Mean (SD)

28.1 (4.33)

28.4 (7.39)

28.2 (4.25)

27.2 (5.94)

 Median [Min, Max]

27.8 [20.9, 34.7]

26.7 [19.7, 50.4]

27.5 [21.9, 34.7]

25.5 [19.7, 44.5]

eTIV

 Mean (SD)

1,560,000 (160,000)

1,540,000 (161,000)

1,220,000 (333,000)

1,150,000 (226,000)

 Median [Min, Max]

1,520,000 [1320000, 1880000]

1,550,000 [1200000, 1920000]

1,140,000 [830000, 1740000]

1,080,000 [754000, 1650000]

Age of onset

 Mean (SD)

 

15.3 (7.11)

 

15.0 (5.79)

 Median [Min, Max]

13.0 [4.00, 33.0]

15.0 [4.00, 31.0]

Number of previous episodes

  Mean (SD)

 

2.58 (2.27)

 

2.30 (2.74)

 Median [Min, Max]

1.00 [1.00, 9.00]

1.00 [0, 9.00]

MADRS

 Baseline (mean, 95% CI)

1.6 [1, 2.4]

31.6 [29, 34.1]

1.6 [1, 2.4]

33.3 [31, 35.2]

 Acute

 Acute

Ketamine

Placebo

1 [0, 1.7]

0.1 [− 0, 0.3]

29.4 [26, 32.7]

32.7 [30, 35.0]

0.9 [0, 1.6]

0.2 [− 0, 0.4]

27.7 [24, 31.6]

33.1 [31, 35.6]

 Interim

 Interim

Ketamine

Placebo

1.7 [1, 2.9]

0.7 [0, 1.3]

23.3 [19, 27.4]

31 [29, 33.4]

1.9 [− 0, 3.9]

0.2 [− 0, 0.5]

25.2 [21, 29.5]

31.2 [28, 34.1]

  1. HV healthy volunteer, TRD treatment-resistant depression, BMI body mass index, eTIV estimated total intracranial volume, MADRS montgomery-asberg depression rating scale.
Back to article page